QUANTRO wins Austrian FFG grant to build AI drug discovery platform
What's the deal? QUANTRO TherapeuticsDealroom has a profile for this one. Try Dealroom → has secured a non-dilutive grant from the Austrian Research Promotion Agency (FFG)Dealroom has a profile for this one. Try Dealroom → to develop ASCEND, its AI-driven medicinal chemistry platform. The 12-month grant will fund work on finding and optimising drugs that target transcription factors. The amount was not disclosed.
What's the endgame? ASCEND combines QUANTRO's time-resolved transcriptomic data with molecular modeling and machine-learning tools to generate and refine drug candidates. The company is targeting transcription factors, long considered difficult to drug.
Why now? The grant builds on an earlier €1.7 million FFG-backed project to scale QUANTRO's screening platform. In January 2025, the company reported a first 10-target multiplex-screening campaign that produced validated hits.
Chief executive officer Michael Bauer said the platform could cut costs and development timelines by up to 50%. He added that its scalability extends beyond oncology into other therapeutic areas, and that ASCEND will rely largely on local infrastructure.
What could go wrong? This is a modest, non-dilutive grant, not a major financing event. Its significance will hinge on demonstrable drug-candidate progress rather than the AI label alone.
The signal: AI-enabled drug discovery is drawing larger private bets. In October 2026, Barcelona-based ALLOXDealroom has a profile for this one. Try Dealroom → raised $10.5 million for a platform also aimed at hard-to-drug targets, and major pharma partnerships point to growing commercial interest. For QUANTRO, the grant is a step toward integrating its platform and advancing its pipeline.
Read more: webdisclosure.fr
Image credit: Generated with Gemini
